Business Overview / Sources of Revenue

Harrow Inc. (HROW) is an eyecare pharmaceutical company focused on ophthalmic products in the U.S., operating through **Branded Pharmaceuticals**, **ImprimisRx** (compounded medications), and **Strategic Holdings & Pipeline** segments[1][2].

It earns revenue primarily by acquiring/licensing FDA-approved branded drugs (e.g., VEVYE, Verkazia, IHEEZO, TRIESENCE) for commercialization via its sales/distribution network and "Access for All" patient affordability program, and through ImprimisRx's compounding/distribution to eye care professionals[1][2].

No exact percentage breakdown is available; branded pharmaceuticals are the core growth driver, while ImprimisRx provides steady cash flow (TTM revenue: $272.3M)[1][2].

Revenue Growth Potential and Recurrence

**Harrow (HROW) does not disclose a large share of recurring revenue**, with growth driven by expanding ophthalmic product adoption (e.g., VEVYE, IHEEZO) rather than specified recurring streams.[1][2]

Revenue grew **36% in 2025 to $272.3M** (from $199.6M in 2024), with historical CAGR of **32.6%**.[1][2] For 2026, guidance projects **$350M-$365M** (~28-34% growth), fueled by early-stage launches, retina practice adoption (70% of 2025 demand), and biosimilars; H1: $133M-$153M, H2: $203M-$226M.[1] Over 5+ years, **strong potential persists** from product traction and cash flow positivity ($43.9M in 2025), though unprofitability lingers.[1][2]

(98 words)

Economic Moat Factors

**Harrow Inc. (HROW) possesses a **moderate economic moat** in the ophthalmic pharmaceutical niche, driven by its integrated platform rather than insurmountable barriers like patents or network effects.**[1][2]

Key strengths include **unique breadth** across FDA-approved drugs, large-scale compounding (ImprimisRx), and equity stakes—**nearly unmatched by competitors**—enabling a "unified commercial flywheel" for cross-selling to 15,000+ eye specialists via one salesforce.[1][2][3] This yields **economies of scale** and operating leverage, with SG&A lagging revenue growth on a capital-light acquisition model.[2] Patient access programs (HAFA) boost adoption with $0–$59 out-of-pocket caps.[3]

However, **low switching costs** for doctors, absence of strong brand power or network effects, and vulnerability to quality issues across verticals limit durability.[1] No truly proprietary assets beyond execution edge.[2]

(98 words)

Leadership

**Mark Baum** is Harrow's **founder and CEO**, appointed in April 2012 with nearly 14 years of tenure.[1] He holds an 8.02% ownership stake worth approximately $108.55 million and earns $1.36 million in annual compensation.[1] **Andrew Boll**, co-founder and President/CFO, has been with the company since its early years, holding roughly 2% of shares outstanding.[3] The broader management team has an average tenure of only 1.2 years, indicating recent turnover, though the board averages 3.1 years tenure.[1] Recent leadership appointments include **Frank Mullery** as CEO of the ImprimisRx subsidiary, bringing over 20 years of healthcare industry experience.[2]

Financial Health

Harrow (HROW) shows mixed financial health: strong liquidity (current ratio 2.72) and low bankruptcy risk (Altman Z-Score 4.42), but high leverage (debt-to-equity 5.36) yields a weak cash-to-debt ratio, making the balance sheet **unhealthy** amid $72.9M cash.[1][2]

It does not generate positive free cash flow (TTM -$75.1M loss); margin is negative (no exact % given).[3]

Shares have been dilutive, not repurchased (no buyback data; high P/B 42.2 signals potential dilution).[1] (78 words)

Last updated Mar 14, 2026